Phase 3Withdrawn
Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL
A Randomized, Double-blind, Placebo-controlled, Multicenter Study Evaluating the Efficacy, Safety, Tolerability, and Coronary Plaque Effects of Early Pelacarsen (TQJ230) Initiation in Patients in the US With Elevated Lp(a) and Recent Acute Coronary Syndrome
- Sponsor
- Novartis Pharmaceuticals (Industry)
- Conditions
- Acute Coronary Syndrome (ACS)
- Interventions
- Pelacarsen; Placebo
- Ages
- adults, older adults
- Registry
- NCT07625306
Full record on ClinicalTrials.gov
From the registry
CTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in participants with elevated Lp(a) and recent acute coronary syndrome (ACS).
Primary outcomes
- Change in log-transformed Lp(a) concentration
History
Primary completion expected
Last registry update
Started
Registered